ABT Molecular Imaging, Inc.


Our

NEWS

ABT Molecular Imaging Raises $6 Million to Continue Growth of Biomarker Generator

Medical imaging company raises growth capital to expand commercialization, technology

KNOXVILLE, TN – September 13, 2012 – ABT Molecular Imaging, a medical imaging company selling a production platform to generate unit doses of molecular imaging drugs, announced today it has secured a $6 million round of financing.

River Cities Capital Funds led the Series C financing, with new investors Limestone Fund, LLC and Council & Enhanced Tennessee Fund, LLC participating. Intersouth Partners, the company's first institutional investor, also participated. Concurrent with the financing round, Rik Vandevenne of River Cities Capital Funds joined the ABT Board of Directors.

ABT will use the money to continue implementing its commercialization strategy, expanding its team and developing its technology to increase its efficiency and expand its flexibilty.

ABT's technology produces doses of molecular imaging drugs for positron emission tomography (PET scanning) at the point of use. PET scanners map the body by means of injectable radioactive drugs that allow PET machines to highlight areas of abnormal metabolic function indicative of disease (such as cancer, Alzheimer's disease, cardiac abnormalities, etc.). This imaging drug production currently requires massive and expensive machinery, generally limiting its use to large academic medical centers and large pharmaceutical manufacturers in certain geographies.

ABT's Biomarker Generator enables rapid, safe and local production of PET imaging agents in a way that is more convenient, versatile and significantly less expensive than current methods available. It is currently deployed to several research and clinical sites with installations in the U.S., Europe and South America. The company was founded by industry veteran Ronald Nutt, Ph.D., a leader in the molecular imaging industry.

"This is an exciting time for ABT – we have ambitious goals and are driving forward to achieve them," said Tom Welch, President and CEO of ABT Molecular Imaging. "This capital will allow us to continue developing critical biomarkers while rolling out our Generator to the many organizations that are interested in making PET scans more accessible for their clinical and research needs."

"ABT is helping to expand the utilization of PET imaging globally," said Rik Vandevenne, Director at River Cities Capital Fund. "The ABT Biomarker Generator is a huge step forward in providing a fully integrated solution at a far lower initial investment and a fraction of the operating costs of a traditional radiopharmacy lab. This is especially important internationally where cost, availability of trained personnel and complexity have traditionally limited the adoption of PET."

About ABT
Molecular Imaging ABT Molecular Imaging is a medical imaging company marketing its Generator, a production platform which produces unit doses of molecular imaging drugs for positron emission tomography (PET) at the point of use, eliminating the need for chemistry and physics expertise. The company was founded in 2006 by industry experts in the molecular imaging industry.

Contact
Tom Welch, CEO
ABT Molecular Imaging
865-982-0098